PortalPublikationenContinuous intravenous administration of vancomycin in medic...

Continuous intravenous administration of vancomycin in medical intensive care unit patients

Standard

Continuous intravenous administration of vancomycin in medical intensive care unit patients. / Saugel, Bernd; Nowack, Marisa C M; Hapfelmeier, Alexander; Umgelter, Andreas; Schultheiss, Caroline; Thies, Philipp; Phillip, Veit; Eyer, Florian; Schmid, Roland M; Huber, Wolfgang.

in: J CRIT CARE, Jahrgang 28, Nr. 1, 01.02.2013, S. 9-13.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Saugel, B, Nowack, MCM, Hapfelmeier, A, Umgelter, A, Schultheiss, C, Thies, P, Phillip, V, Eyer, F, Schmid, RM & Huber, W 2013, 'Continuous intravenous administration of vancomycin in medical intensive care unit patients', J CRIT CARE, Jg. 28, Nr. 1, S. 9-13. https://doi.org/10.1016/j.jcrc.2012.02.003

APA

Saugel, B., Nowack, M. C. M., Hapfelmeier, A., Umgelter, A., Schultheiss, C., Thies, P., Phillip, V., Eyer, F., Schmid, R. M., & Huber, W. (2013). Continuous intravenous administration of vancomycin in medical intensive care unit patients. J CRIT CARE, 28(1), 9-13. https://doi.org/10.1016/j.jcrc.2012.02.003

Vancouver

Saugel B, Nowack MCM, Hapfelmeier A, Umgelter A, Schultheiss C, Thies P et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. J CRIT CARE. 2013 Feb 1;28(1):9-13. https://doi.org/10.1016/j.jcrc.2012.02.003

Bibtex

@article{40a535fae6e74a179b019f67aad1fafa,
title = "Continuous intravenous administration of vancomycin in medical intensive care unit patients",
abstract = "PURPOSE: The aim of this study was to evaluate continuous vancomycin infusion (contV) in intensive care unit patients.MATERIALS AND METHODS: A retrospective study in 164 patients treated with contV was conducted. They were compared with 75 patients treated with intermittent vancomycin infusion.RESULTS: The median duration of vancomycin therapy in the contV group was 6 (5%-95% percentile range, 2-21) days. The median daily vancomycin dose in the contV group was 960 (526-1723) mg, resulting in a median serum vancomycin plateau concentration of 19.8 (9.8-29.4) mg/L (target: 15-25 mg/L). The contV administration regime was sufficient regarding achievement of the target serum vancomycin concentration. However, in the contV group, serum vancomycin levels were frequently in a subtherapeutic range on treatment days 1 (44%), 2 (29%), and 3 (23%). In the contV group, serum vancomycin concentration determinations per treatment day were performed significantly less often compared with the intermittent vancomycin infusion group (0.38 [0.15-0.75] vs 0.43 [0.22-1.00], P = .041).CONCLUSIONS: In medical intensive care unit patients, contV is sufficient to achieve target serum vancomycin concentrations. Because contV frequently resulted in subtherapeutic drug levels on the first days of therapy, a higher loading or starting dose might be necessary.",
keywords = "Anti-Bacterial Agents, Area Under Curve, Case-Control Studies, Drug Administration Schedule, Drug Monitoring, Female, Germany, Humans, Infusions, Intravenous, Intensive Care Units, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Sepsis, Vancomycin",
author = "Bernd Saugel and Nowack, {Marisa C M} and Alexander Hapfelmeier and Andreas Umgelter and Caroline Schultheiss and Philipp Thies and Veit Phillip and Florian Eyer and Schmid, {Roland M} and Wolfgang Huber",
note = "Copyright {\textcopyright} 2013 Elsevier Inc. All rights reserved.",
year = "2013",
month = feb,
day = "1",
doi = "10.1016/j.jcrc.2012.02.003",
language = "English",
volume = "28",
pages = "9--13",
journal = "J CRIT CARE",
issn = "0883-9441",
publisher = "Elsevier BV",
number = "1",

}

RIS

TY - JOUR

T1 - Continuous intravenous administration of vancomycin in medical intensive care unit patients

AU - Saugel, Bernd

AU - Nowack, Marisa C M

AU - Hapfelmeier, Alexander

AU - Umgelter, Andreas

AU - Schultheiss, Caroline

AU - Thies, Philipp

AU - Phillip, Veit

AU - Eyer, Florian

AU - Schmid, Roland M

AU - Huber, Wolfgang

N1 - Copyright © 2013 Elsevier Inc. All rights reserved.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - PURPOSE: The aim of this study was to evaluate continuous vancomycin infusion (contV) in intensive care unit patients.MATERIALS AND METHODS: A retrospective study in 164 patients treated with contV was conducted. They were compared with 75 patients treated with intermittent vancomycin infusion.RESULTS: The median duration of vancomycin therapy in the contV group was 6 (5%-95% percentile range, 2-21) days. The median daily vancomycin dose in the contV group was 960 (526-1723) mg, resulting in a median serum vancomycin plateau concentration of 19.8 (9.8-29.4) mg/L (target: 15-25 mg/L). The contV administration regime was sufficient regarding achievement of the target serum vancomycin concentration. However, in the contV group, serum vancomycin levels were frequently in a subtherapeutic range on treatment days 1 (44%), 2 (29%), and 3 (23%). In the contV group, serum vancomycin concentration determinations per treatment day were performed significantly less often compared with the intermittent vancomycin infusion group (0.38 [0.15-0.75] vs 0.43 [0.22-1.00], P = .041).CONCLUSIONS: In medical intensive care unit patients, contV is sufficient to achieve target serum vancomycin concentrations. Because contV frequently resulted in subtherapeutic drug levels on the first days of therapy, a higher loading or starting dose might be necessary.

AB - PURPOSE: The aim of this study was to evaluate continuous vancomycin infusion (contV) in intensive care unit patients.MATERIALS AND METHODS: A retrospective study in 164 patients treated with contV was conducted. They were compared with 75 patients treated with intermittent vancomycin infusion.RESULTS: The median duration of vancomycin therapy in the contV group was 6 (5%-95% percentile range, 2-21) days. The median daily vancomycin dose in the contV group was 960 (526-1723) mg, resulting in a median serum vancomycin plateau concentration of 19.8 (9.8-29.4) mg/L (target: 15-25 mg/L). The contV administration regime was sufficient regarding achievement of the target serum vancomycin concentration. However, in the contV group, serum vancomycin levels were frequently in a subtherapeutic range on treatment days 1 (44%), 2 (29%), and 3 (23%). In the contV group, serum vancomycin concentration determinations per treatment day were performed significantly less often compared with the intermittent vancomycin infusion group (0.38 [0.15-0.75] vs 0.43 [0.22-1.00], P = .041).CONCLUSIONS: In medical intensive care unit patients, contV is sufficient to achieve target serum vancomycin concentrations. Because contV frequently resulted in subtherapeutic drug levels on the first days of therapy, a higher loading or starting dose might be necessary.

KW - Anti-Bacterial Agents

KW - Area Under Curve

KW - Case-Control Studies

KW - Drug Administration Schedule

KW - Drug Monitoring

KW - Female

KW - Germany

KW - Humans

KW - Infusions, Intravenous

KW - Intensive Care Units

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Retrospective Studies

KW - Sepsis

KW - Vancomycin

U2 - 10.1016/j.jcrc.2012.02.003

DO - 10.1016/j.jcrc.2012.02.003

M3 - SCORING: Journal article

C2 - 22459156

VL - 28

SP - 9

EP - 13

JO - J CRIT CARE

JF - J CRIT CARE

SN - 0883-9441

IS - 1

ER -